News Post

Piramal Alternatives invests ₹110 cr in Biodeal Pharmaceuticals

Livemint

· 2m
placeholder-image

Piramal Alternatives, the fund management business of the Piramal Group, is investing ₹110 crore in Biodeal Pharmaceuticals Ltd, a contract development and manufacturing organization. The investment will be used to improve infrastructure, upgrade technology, and expand Biodeal's nutraceuticals manufacturing facility. Biodeal specializes in contract manufacturing nasal sprays for international and domestic pharmaceutical companies. The capital infusion will enable Biodeal to develop a new facility in compliance with USFDA accreditations and increase production capacity by three times. This investment is in line with Piramal Alternatives' commitment to provide flexible and value-accretive capital to support Biodeal's growth.

No Comments yet

Download the medial app to read full posts, comements and news.